In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory ...

Both of these late-stage studies were using the company's drug povorcitinib to treat patients with Hidradenitis Suppurativa [HS]. Both of these trials met their respective primary endpoints and ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

Data showed a significantly higher proportion of patients treated with povorcitinib once daily (QD) compared with placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR) and a greater ...

WILMINGTON, DE — Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for ...

On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne ...

Following the povorcitinib/povo Phase3 results in moderate to severe hidradenitis suppurativa, HS, the firm believes that the data were statistically significant but missed expectations on ...

Topline data were announced from two pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa (HS). The randomized, double-blind, placebo-controlled ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Based on the Phase 3 top-line results from two pivotal trials evaluating povorcitinib in hidradenitis suppurativa, the firm lowered its pipeline estimates, which contributes to a price target ...